PBAC's latest decision on Darbepoetin alfa: Recommended with restriction (2019). Considered for Treatment of moderate to severe chemotherapy-induced anaemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies with haemoglobin level less than 100 g per L.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
2
first 2007
PBS spend
$79M
84,772 scripts · 2024
Eligible population
Patients with chemotherapy-induced anaemia receiving myelosuppressive chemotherapy for non-myeloid malignancies with haemoglobin level less than 100 g per L
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
Study 782
Comparator
standard medical management (placebo or no pharmacological treatment), includes blood transfusions where clinically indicated
Economic model
CUA
ICER note
ICER values are redacted in the public summary document
PBS expenditure
The Australian government paid $79M in PBS benefits for Darbepoetin alfa in 2024 across 84,772 scripts, at $926 per script.
Submission history
Nov 2007: Not recommended
Mar 2019: Recommended with restriction · Authority Required